Novocure Receives FDA Approval for Second Generation Optune System Second generation Optune system is less than half the weight and size of first generation Optune system New system aims to make ...
The FDA has approved a lighter and more convenient version of the tumor-treating field device Optune for patients with glioblastoma multiforme. The FDA has approved a lighter and more convenient ...
ST. HELIER, Jersey--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) announced today that the State of Israel Ministry of Health has added Optune in combination with temozolomide to the Israeli medical ...
The approval was based on findings from the phase 3 EF-14 trial. The FDA has expanded the indication for Optune (NovoTTF-100A System) in combination with Temodar (temozolomide) as a treatment for ...
Optune Lua, formerly known as NovoTTF-100L, is the first FDA-approved treatment for malignant pleural mesothelioma in over 15 years ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) ...
St. Helier, Jersey Isle's Novocure ($NVCR) submitted a PMA supplement with the FDA, in hopes of marketing an upgraded version of its noninvasive Optune system to ...
SHREVEPORT, La. (Press Release) - Willis-Knighton Cancer Center is now offering Optune, a medical device that, when used in conjunction with partial-brain radiotherapy and chemotherapy, has been shown ...
NovoCure Ltd., which makes a device that uses electrical fields to fight a common form of brain cancer, has disclosed plans for an initial public offering. NovoCure’s Optune system is a treatment for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results